Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK/Desano Tie-Up To Bring Large Dolutegravir Price Cuts

This article was originally published in PharmAsia News

Executive Summary

HIV drug Tivicay is expected to become cheaper in China under a recent manufacturing deal between ViiV and Desano. The Chinese firm expects to gain a 35% share of the global generic antiretroviral API supply market this year after patent licensing agreements with the Medicines Patent Pool.

You may also be interested in...



FDA Warning Letter Could Impact Zhejiang Medicine’s US Foray

Zhejiang Medicine has become the latest major Chinese API firm to be hit with a US FDA warning letter amid stepped up oversight of production facilities in China by the US regulator, which has led to a string of similar actions this year alone. But efforts are now being made both by Chinese manufacturers and by authorities in the two countries to ensure adherence to international standards.

FDA Warning Letter Could Hamper Zhejiang Medicine’s US Foray

A recent US FDA warning letter could affect efforts by major Chinese API firm Zhejiang Medicine to build its US business, amid falling North American exports from China and a string of similar warnings over the past few years. But efforts are being made both by Chinese manufacturers and by US and Chinese regulators to ensure adherence to international standards.

China’s First Home Grown Novel HIV Drug Shoots For Prime Time

With a fast-growing HIV population and reliance on older-generation treatments, China could become the next frontier for new antiretroviral drugs. Government support might see the country’s first novel locally developed, long-lasting injectable product take on the big names in the field.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC089107

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel